A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors
Status:
Unknown status
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
hPV19 is a monoclonal antibody (mAb) directed against vascular endothelial growth factor
(VEGF). hPV19 binds to human VEGF with unique binding site on VEGF different from that of
Bevacizumab(Avastin) and inhibits the binding of VEGF to it's receptors, VEGF-R1 and VEGF-R2.
By preventing VEGF binding to its receptors, growth of tumor blood vessels are inhibited and
tumor growth prevented or slowed. In this study we are investigating the tolerability,
safety, pharmacokinetics and anti-tumor activity of hPV19 in combination with chemotherapy in
patients with solid tumors. hPV19 will give to patients by intravenous(i.v.) infusion with a
single and multiple doses.